Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give Karyopharm a consensus "Moderate Buy" from eight covering firms (1 sell, 6 buy, 1 strong buy) with an average 12‑month target of about $14.29.
• Broker actions are mixed: several firms recently lowered targets (HC Wainwright to $8 from $15; Robert W. Baird to $15 from $21; Piper Sandler to $8 from $12) while Rodman & Renshaw upgraded to a strong-buy.
• Shares opened at $5.89 with a market cap near $108M, 50/200‑day SMAs of $7.67/$6.80 and a one‑year range of $3.51–$10.99; the company is currently loss‑making (expected ~‑0.71 EPS) but sells the approved drug selinexor (XPOVIO) and has additional SINE‑class pipeline programs.

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $14.2857.

Several equities analysts have recently commented on the company. HC Wainwright decreased their price target on Karyopharm Therapeutics from $15.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, March 25th. The Goldman Sachs Group set a $12.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Robert W. Baird decreased their target price on shares of Karyopharm Therapeutics from $21.00 to $15.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 25th. Rodman & Renshaw raised shares of Karyopharm Therapeutics to a "strong-buy" rating in a research note on Tuesday, March 10th. Finally, Piper Sandler reiterated an "overweight" rating and set a $8.00 price target (down from $12.00) on shares of Karyopharm Therapeutics in a research report on Monday.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $5.89 on Friday. The company has a 50 day simple moving average of $7.67 and a 200-day simple moving average of $6.80. The company has a market capitalization of $108.02 million, a P/E ratio of -0.35 and a beta of 0.40. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its quarterly earnings data on Friday, February 13th. The company reported ($2.23) EPS for the quarter, beating analysts' consensus estimates of ($2.26) by $0.03. The business had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million. As a group, research analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LLC acquired a new position in Karyopharm Therapeutics during the fourth quarter worth $74,000. Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at $45,000. State Street Corp raised its holdings in shares of Karyopharm Therapeutics by 27.2% in the 4th quarter. State Street Corp now owns 58,942 shares of the company's stock valued at $434,000 after buying an additional 12,600 shares during the period. Tudor Investment Corp ET AL acquired a new position in Karyopharm Therapeutics during the 4th quarter worth about $95,000. Finally, XTX Topco Ltd purchased a new position in Karyopharm Therapeutics during the 2nd quarter valued at about $56,000. Hedge funds and other institutional investors own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics NASDAQ: KPTI is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company's lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm's pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.